RE:Links to Filings Thanks for posting. I see nothing new in any business updates and the use of proceeds is the vague list of all their expense lines - R&D, SG&A, general Corp, etc.... So we have to assume that the pressure we have applied and that they have acknowledged to get a serious biotech analyst in the US to cover them in their entirety is one reason they've done this. I appreciate that fact given they desperately need some serious coverage from a good US analyst. I would have to say they listened to us on that aspect and did what they needed to do. We need that research BEFORE these cancer milestones are hit.
All we can hope for is that since there is no clear desperate need for cash is that they take their time, hit some milestones and some pricing spikes, and feed a bit into that. This accomplishes 3 goals we have argued for -better coverage in US, new large clients, increased activity at higher price levels. Cash at the right price is OK and I suppose it may help if cancer moves rapidly and they need to build sales and manufacturing apparatus or contracts. Let's watch and see how this works out but it's entirely in their control to make this a plus-plus-plus for some of the things we have spoken about. Anyone who also was critical of the analytical coverage and low volume should be pleased if this is done well. You can't bash them for fixing a bit of what we were critical of. As for Scarlets retail strategy, it's wait and see but this, and a solid report, may give them an incentive to push harder there.
A good question is, when do they expect Cantor to pick up coverage?